Yes, he really did an impressive job presenting a
Post# of 30028
Interesting that it wasn't until May that amarantus became really interested in acquiring ESS - GC said that the fda removed the clinical hold on ESS in May so figure ambs took up to 7 months to negotiate this agreement.
I like GC's value investing approach re: acquiring distressed drugs and diagnostics like lympro and ESS. It reminds me of Warren Buffett's investing philosophy and that's sort of worked out okay for Buffett.